. 2018 May 10;13(5):e0197298. doi: 10.1371/journal.pone.0197298

Table 1. Patient Demographics, HHV8 DNA and Antibody Positivity, and clinical Details for participants with non-KS malignancies.

Pt	Sex	HHV8 Antibody	HHV8 DNA	ART at Time of Sampling	Clinical Diagnosis	Cancer Treatment
7	M	-	+	No	NHL	N/A
8^a	F	-	-	No	NHL	R-CODOX-M/IVAC
9	M	-	+	Yes	NHL	R-EPOCH
10	M	-	+	Yes	NHL	R-CHOP
11	M	-	-	Yes	NHL	CHOP, GDP,
12	M	-	-	Yes	NHL	R-CHOP,
13	M	+	-	No	NHL	R-CHOP
14	M	-	-	Yes	NHL	R-CHOP
15^a	M	+	+	Yes	NHL	R-EPOCH, DHAP
16	M	+	-	Yes	NHL	R-CHOP, R-ICE
17	M	+	-	Yes	NHL	R-EPOCH
18	M	-	-	No	NHL	EPOCH, R-ICE
19	M	-	-	-^b	NHL	R-EPOCH
20	M	-	-	Yes	NHL	R-ICE
21	M	-	-	Yes	HL	ABVD
22	M	-	-	Yes	HL	ABVD
23	M	-	-	Yes	AML	Cytarabine-based
24	M	-	-	Yes	RCC	carboplatin/gemcitabine
25	M	-	-	Yes	HL	Autologous HSCT
26	M	+	-	Yes	HL	Allogeneic HSCT^c
27	M	-	-	Yes	HL	Allogeneic HSCT^c
28	M	+	-	Yes	HL	Allogeneic HSCT^c
29^a	Ma	-	+	Yes	NHL	Allogeneic HSCT^c

Pt = participant; NHL = non-Hodgkin lymphoma; HL = Hodgkin’s Lymphoma; RCC = renal cell carcinoma; AML = acute myeloid leukaemia; R-EPOCH = rituximab, etoposiode, prednisone, vincristine, cyclophosphamide, doxorubicin; R-CODOX-M/IVAC = rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, cytarabine; GDP = R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; DHAP = dexamethasone, cytarabine, cisplatin; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; HSCT = hematopoietic stem cell transplantation;

^a longitudinal data on detectable HHV8 levels were available

^b Unknown

^c Conditioning regimen included busulfan and fludarabine